Wegovy Injection (Semaglutide 2.4mg)

High-dose semaglutide for chronic weight management

Wegovy is the 2.4mg weekly semaglutide injection approved specifically for chronic weight management in adults with obesity. It is clinically proven to produce an average weight loss of 15% of body weight over 68 weeks — significantly more than lifestyle changes alone.

Wegovy is the same active ingredient as Ozempic but at a higher dose specifically optimised for weight loss rather than diabetes management. It is prescribed as part of a medically supervised programme that includes dietary guidance and behaviour support.

Key Benefits

Highest approved semaglutide dose — 2.4mg weekly
Average 15% body weight loss over 68 weeks
Reduces risk of cardiovascular events in obese patients
Established safety profile from large-scale clinical trials

Is This Treatment Right For You?

Adults with BMI 30+ or BMI 27+ with a weight-related condition
Patients who have reached the maximum Ozempic dose and want to escalate
Those needing a medically managed long-term weight programme

What to Expect

Assessment

Medical review, body composition and baseline bloods.

Prescribing

Wegovy prescribed; dose starts at 0.25mg and escalates over 16 weeks to 2.4mg.

Programme Support

Nutritional guidance and behavioural support throughout the programme.

Monitoring

Quarterly blood tests; dose adjusted if side effects require.

Recovery & Aftercare

No downtime; GI side effects (nausea, constipation) are most common in the dose-escalation phase.

Frequently Asked Questions

Is Wegovy available in Abu Dhabi?

Yes — Wegovy (semaglutide 2.4mg) is available at Enfield Royal Clinic Khalifa City by prescription from our licensed physicians following a medical assessment.

What is the difference between Wegovy and Ozempic?

Both contain semaglutide, but Wegovy is dosed up to 2.4mg weekly for weight management, while Ozempic is dosed up to 1mg weekly for type 2 diabetes. Wegovy produces greater average weight loss due to the higher dose.